Health care priority and rare malignant diseases: Orphan therapy in brca 1/2 mutated ovarian cancer-experience from Montenegro

Abstract

Ovarian cancer is not the most common, but certainly remains the deadliest of all gynecological tumour. New molecular genetic studies classify ovarian cancer as type 1 and type 2. Subtype 2 of a serous papillary ovarian cancer of high grade is dominant, aggressive and it is the cause of death in 70-80% of the total number of women. In terms of the therapeutic response, ovarian cancer is divided into platinum-sensitive and platinum-resistant. The latest treatment to maintain the achieved therapeutic response in a relapsed disease, that is platinum responsible and BRCA 1/2 mutated, is the use of PARP inhibitors. EMA has approved the use of a PARP inhibitor as an orphan drug for this indication. Herein, we present two cases and analyze the way in which developing countries, including Montenegro, provide the most modern treatment for these patients.